Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MUSE study of oral colchicine in inflammatory bowel disease
jRCTs061240020Recruiting
- Start
- Aug 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of colchicine in inflammatory bowel disease (IBD), autoimmune colitis and Crohn's disease. Primary endpoint: Clinical response by PRO2 at day 14. Started Aug 2024; status: recruiting.
02
Drugs
colchicine
03
Conditions
inflammatory bowel disease (IBD)autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on jRCTs061240020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061240020.